Supernus Pharmaceuticals SUPN Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's total cost of revenue?
- Supernus Pharmaceuticals (SUPN) reported total cost of revenue of $23.39M in Q1 2026.
- How has Supernus Pharmaceuticals's total cost of revenue changed year-over-year?
- Supernus Pharmaceuticals's total cost of revenue increased by 48.4% year-over-year, from $15.76M to $23.39M.
- What is the long-term trend for Supernus Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's total cost of revenue has grown at a -0.2% compound annual growth rate (CAGR), from $75.06M to $74.56M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.